(Total Views: 283)
Posted On: 06/29/2017 4:00:50 PM
Post# of 72446
Do you actually read the post.
I stated that the other phase 3 costs (not necessarily other mid-stage trials)
will be comparable in cost.
All the PHASE 3 trials will require a much larger number of participants than these smaller phase 2 trials. They will need to be blinded, not open label. A Kevetrin PHASE 3 would be much more expensive than for B-ABSSSI. It would be longer, more extensive for each patient, more demanding on clinicians and the CRO.
You disagree?
I stated that the other phase 3 costs (not necessarily other mid-stage trials)
will be comparable in cost.
All the PHASE 3 trials will require a much larger number of participants than these smaller phase 2 trials. They will need to be blinded, not open label. A Kevetrin PHASE 3 would be much more expensive than for B-ABSSSI. It would be longer, more extensive for each patient, more demanding on clinicians and the CRO.
You disagree?
(3)
(0)
